TGF-ß1 promotes human hepatic carcinoma HepG2 cells invasion by upregulating autophagy.

OBJECTIVE: To study the role of TGF-ß1 in autophagy and invasion ability of human hepatic carcinoma HepG2 cells. MATERIALS AND METHODS: Cultured HepG2 cells were treated with different concentrations of TGF-ß1 for 24 h. The protein expression levels of autophagy relative marker LC3 and Beclin1 were detected by Western blot. The effect of TGF-ß1 on invasion ability of HepG2 cells was detected with transwell method. RESULTS: The results demonstrated that TGF-ß1 was able to activate autophagy of HepG2 cells in a dose-dependent manner. Autophagy inhibitor 3-methyladenine (3-MA) could reverse TGF-ß1 induced autophagy process. Also, TGF-ß1 significantly promotes the invasion ability of HepG2 cells; however, this process could effectively reverse by autophagy inhibitor 3-MA. CONCLUSIONS: TGF-ß1 enhances HepG2 cells invasion by upregulating autophagy.

Multicenter, double-blind, randomized clinical trial of parenterally administered Cefoselis versus Cefepime for the treatment of acute bacterial infections.

AIM: This study aims to evaluate the clinical efficacy and safety of intravenous Cefoselis injection for the treatment of acute moderate and severe bacterial infections. PATIENTS AND METHODS: A multicenter, double-blind, randomized clinical trial was carried out using Cefepime as control. Patients received 1.0 g of either Cefoselis or Cefepime for moderate infections or 2.0 g for severe infections at an interval of 12 hours for 7 to 14 days. A total of 276 patients (138 with Cefoselis, 138 with Cefepime) with respiratory or urinary tract infections were enrolled in the study. Up to 137 and 124 patients receiving Cefoselis and 132 and 125 patients receiving Cefepime were eligible for the ITT (intent to treat) and PP (per protocol) analyses, respectively. RESULTS: At the end of the treatment, the cure rates and effective rates were 59.68% (74/124) and 93.55% (116/124) with Cefoselis, and 56.00% (74/124) and 90.40% (116/124) with Cefepime. The bacterial eradication rates of the two groups were 90.32% and 93.85%, respectively. No statistical differences were observed on the above-mentioned parameters between the two groups (all p > 0.05). Adverse events, mainly mild aminotransferase elevation and mild leukopenia, were observed in 11.59% (16/138) and 13.77% (19/138) of patients with Cefoselis and Cefepime, respectively (p > 0.05). CONCLUSIONS: Cefoselis is an effective and safe choice against acute moderate and severe respiratory infections and UTI (urinary tract infection).

Association of MTHFR C677T polymorphisms and colorectal cancer risk in Asians: evidence of 12.255 subjects

OBJECTIVES: To investigate the relationship of the MTHFR polymorphisms (C677T) and the risk of CRC by meta-analysis. METHODS: Relevant literatures concerning the association between the MTHFR C677T polymorphism and the risk of CRC were searched using the electronic database PubMed, EMBASE, Cochrane and China National Knowledge Infrastructure (CNKI). Odds ratio (ORs) and 95 % confidence intervals (CIs) were determined to assess the gene-disease association using fixed or random effect models, according to the heterogeneity among included studies. RESULTS: The study shows that the MTHFR 677 TT homozygous genotype significantly decreases the risk of CRC in Asians (TT vs. CC: OR = 0.82, 95 % CI 0.73-0.92; TT vs. CT: OR = 0.84, 95 % CI 0.75-0.94; TT vs. CC+TT: OR = 0.83, 95 % CI 0.75-0.93). CONCLUSION: This meta-analysis indicated that the MTHFR 677 TT homozygous genotype decreased the risk of CRC in Asians, while the MTHFR 677 CT heterozygous genotype did not contribute to CRC susceptibility (AU)

No disponible

Association of MTHFR C677T polymorphisms and colorectal cancer risk in Asians: evidence of 12,255 subjects.

OBJECTIVES: To investigate the relationship of the MTHFR polymorphisms (C677T) and the risk of CRC by meta-analysis. METHODS: Relevant literatures concerning the association between the MTHFR C677T polymorphism and the risk of CRC were searched using the electronic database PubMed, EMBASE, Cochrane and China National Knowledge Infrastructure (CNKI). Odds ratio (ORs) and 95 % confidence intervals (CIs) were determined to assess the gene-disease association using fixed or random effect models, according to the heterogeneity among included studies. RESULTS: The study shows that the MTHFR 677 TT homozygous genotype significantly decreases the risk of CRC in Asians (TT vs. CC: OR = 0.82, 95 % CI 0.73-0.92; TT vs. CT: OR = 0.84, 95 % CI 0.75-0.94; TT vs. CC+TT: OR = 0.83, 95 % CI 0.75-0.93). CONCLUSION: This meta-analysis indicated that the MTHFR 677 TT homozygous genotype decreased the risk of CRC in Asians, while the MTHFR 677 CT heterozygous genotype did not contribute to CRC susceptibility.